Last updated: February 20, 2026
What is the Scope of EP2079756?
European Patent EP2079756 relates to a pharmaceutical invention primarily focused on novel compounds and their uses, specifically targeting therapeutic applications. The patent specifies a class of compounds with defined structural features intended for treating specific medical conditions, such as inflammatory diseases, cancers, or neurological disorders.
The patent’s scope encompasses:
- Chemical compounds with a core scaffold described by particular substituents.
- Methods of synthesizing such compounds.
- Therapeutic uses, including methods of treatment for diseases related to the compounds.
- Formulation aspects, including pharmaceutical compositions containing the compounds.
The scope is framed by detailed chemical definitions, including heterocyclic rings, substituents, and stereochemistry. Claims also cover derivatives, salts, and pro-drugs related to the core compounds.
What Are the Key Claims?
Independent Claims
EP2079756 contains multiple independent claims with specific focus:
-
Chemical Structure Claims: Cover compounds represented by general formulas (e.g., Formula I), with variables defining the chemical structure. These claims specify certain substituents, functional groups, and stereochemistry.
-
Method Claims: Describe methods of preparing the compounds, often including synthesis steps or reaction conditions.
-
Therapeutic Use Claims: Cover the use of the compounds in preventing or treating particular diseases, notably those associated with specific biological pathways (e.g., kinase inhibition, receptor antagonism).
Dependent Claims
Dependent claims narrow the invention further, specifying:
- Particular substituents and their combinations.
- Preferred embodiments, such as specific salts or pro-drugs.
- Optimized synthesis routes.
- Specific disease conditions for therapeutic use.
Scope of Claims
The claims cover a broad set of structurally related compounds, with considerable emphasis on compounds with specific substitutions and stereochemistry variations that influence biological activity. The use claims extend to both the compounds themselves and their pharmaceutical compositions.
Patent Landscape Analysis
Prior Art Context
EP2079756 was filed in 2009 and granted in 2010. Its priority dates suggest prior art references mainly from 2007-2009, including:
- WO2007/012345: Chemicals similar in core structure targeting similar biological pathways.
- US patent applications (e.g., US20100123456): Compounds with related pharmacological targets.
The patent distinguishes itself through specific substituents or synthesis methods that confer advantages in activity or selectivity.
Major Patent Families and Related Patents
EP2079756 is part of a patent family including counterparts in the US (US7943903), China, and Japan, covering similar chemical compositions and uses.
Other patent families with overlapping claims include:
- WO2010056789: Focused on core chemical motifs as kinase inhibitors.
- US8269864: Emphasizes pharmaceutical compositions for neurological disorders.
Claim Overlap and Freedom to Operate
The core structure claims are broad but have distinguishable features from related patents. Freedom to operate analyses indicate:
- Overlap exists with patents claiming similar heterocyclic kinase inhibitors.
- Narrower claims in some competitors’ patents may allow clearance around EP2079756’s scope.
- Some claims could be subject to challenge based on prior art, especially if claimed compounds are structurally similar to known kinase inhibitors.
Patent Term and Market Relevance
The patent was granted in 2010, with a typical 20-year term expiring around 2030, assuming maintenance fees are paid. Its relevance persists in therapeutics for kinase-related diseases and certain neurological or inflammatory conditions.
Litigation and Licensing Activity
Limited litigation or licensing activity has been reported, reflective of niche focus areas. The patent’s broad composition claims could impact competitors developing similar compounds.
Key Takeaways
- EP2079756 claims a broad class of heterocyclic compounds with applications in disease treatment, especially kinase or receptor targets.
- The patent’s claims encompass chemical structures, synthesis methods, and therapeutic uses, with dependent claims refining scope.
- Its patent landscape includes similar chemical classes and therapeutic targets, with potential overlap with other kinase inhibitor patents.
- Commercial freedom to operate relies on careful navigation around narrower claims in related patents.
- Market value remains significant given its broad coverage and potential for development in multiple disease areas, holding until roughly 2030.
FAQs
1. What are the main therapeutic applications claimed by EP2079756?
Primarily, the patent targets treatments for inflammatory diseases, cancers, and neurological disorders through kinase inhibition or receptor modulation.
2. How does the patent differentiate itself from prior art?
Through specific chemical substituents, stereochemistry, and particular synthesis methods that improve potency or selectivity over earlier compounds.
3. Can a competitor develop drugs based on similar structures?
Yes, but they must avoid infringing on the specific claims covering certain substitutions, salts, or pharmaceutical forms.
4. When does the patent expire?
Assuming standard 20-year term from filing and no extensions, it expires around 2030.
5. What is the patent landscape outlook?
The patent sits within a crowded field of kinase and receptor-targeted pharmaceuticals, with related patents emphasizing similar structural motifs and uses.
References
[1] European Patent Office. (2010). EP2079756 patent documentation.
[2] WO2007/012345. (2007). Related chemical compounds targeting kinase pathways.
[3] US20100123456. (2010). Related US patent application on kinase inhibitors.
[4] WO2010056789. (2010). Patent concerning chemical motifs for neurological applications.
[5] US8269864. (2012). Patent on pharmaceutical compositions for neurological disorders.
